More Evidence that Veyonda Enhances RT in Prostate Cancer
Filed with ASX · · 6 pages · English
Story so far
Earlier from Noxopharm
- NOX Receives FY19 Federal Government R&D Tax Rebate
- Pre-Clinical Evidence Confirms Veyonda Abscopal Effect
- Noxopharm August 2019 Corporate Presentation
- NOX Announces AU$26 Million Funding Facility
- Conference Hears of Positive Interim Data from LuPIN Trial
Later from Noxopharm
- Appendix 4E and Audited Financial Statements FY19
- Veyonda and Radiotherapy Profiled at Key Oncology Meeting
- Further Review Shows Major Clinical Benefits from Veyonda
- Potential Fundamental Change in Treatment of Brain Cancer
- Durable Anti-Cancer Effect Confirmed in DARRT-1 Study
Follow Noxopharm into a list and get an email when it puts out news.
Follow Noxopharm